Irinotecan-induced immune thrombocytopenia.
Medical City Dallas Hospital (BCM), Dallas, Texas Department of Medicine (JNG), College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma Platelet and Neutrophil Immunology Laboratory and Blood Research Institute (RHA, BRC), Blood Center of Wisconsin and Medical College of Wisconsin, Milwaukee, Wisconsin.
Barry C
BC
Mirtsching
James N
JN
George
Richard H
RH
Aster
Brian R
BR
Curtis
D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000276:immunology / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000188:drug therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D010976:Platelet Count; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000276:immunology
D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic; D000068258:Bevacizumab; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin